Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis.
Nguyen HN, Jeong Y, Kim Y, Kamiya M, Kim Y, Athar H, Castaldi PJ, Hersh CP, Menon JA, Wong J, Chan I, Oldham WM, Padera RF, Sharma NS, Sholl LM, Vivero M, Watts GFM, Knipe RS, Black KE, Hariri LP, Yun JH, Merriam LT, Yuan K, Kim EY, Brenner MB. Nguyen HN, et al. Among authors: sholl lm. Proc Natl Acad Sci U S A. 2024 Dec 10;121(50):e2401899121. doi: 10.1073/pnas.2401899121. Epub 2024 Dec 5. Proc Natl Acad Sci U S A. 2024. PMID: 39636853
Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis.
Nguyen HN, Jeong Y, Kim Y, Kim YH, Athar H, Castaldi PJ, Hersh CP, Padera RF, Sholl LM, Vivero M, Sharma NS, Yun J, Merriam LT, Yuan K, Kim EY, Brenner MB. Nguyen HN, et al. Among authors: sholl lm. bioRxiv [Preprint]. 2024 May 23:2024.05.21.595153. doi: 10.1101/2024.05.21.595153. bioRxiv. 2024. Update in: Proc Natl Acad Sci U S A. 2024 Dec 10;121(50):e2401899121. doi: 10.1073/pnas.2401899121 PMID: 38826450 Free PMC article. Updated. Preprint.
Clinicogenomic characterization of inflammatory breast cancer.
Priedigkeit N, Harrison B, Shue R, Hughes M, Li Y, Kirkner GJ, Spurr LF, Remolano MC, Strauss S, Files J, Feeney AM, Grant L, Mohammed-Abreu A, Garrido-Castro A, Sousa RB, Bychkovsky B, Nakhlis F, Bellon JR, King TA, Winer EP, Lindeman N, Johnson BE, Sholl L, Dillon D, Overmoyer B, Tolaney SM, Cherniack A, Lin NU, Lynce F. Priedigkeit N, et al. bioRxiv [Preprint]. 2024 May 10:2024.05.07.592972. doi: 10.1101/2024.05.07.592972. bioRxiv. 2024. PMID: 38766070 Free PMC article. Preprint.
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer.
Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi CAM, Murilo Hidalgo Filho C, Di Federico A, Jabar F, Hashemi S, Houda I, Richardsen E, Rasmussen Busund LT, Donnem T, Bahce I, Pinato DJ, Helland Å, Sholl LM, Awad MM, Kwiatkowski DJ. Rakaee M, et al. Among authors: sholl lm. JAMA Oncol. 2024 Dec 26. doi: 10.1001/jamaoncol.2024.5356. Online ahead of print. JAMA Oncol. 2024. PMID: 39724105
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Pecci F, Makarem M, Gandhi MM, Garbo E, Saini A, De Giglio A, Favorito V, Scalera S, Cipriani L, Marinelli D, Haradon D, Nguyen T, Haradon J, Voligny E, Vaz V, Gelsomino F, Sperandi F, Melotti B, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Lindsay J, Rodig SJ, Pfaff K, Sholl LM, Wang X, Johnson BE, Jänne PA, Rekhtman N, Maugeri-Saccà M, Heist RS, Ardizzoni A, Awad MM, Arbour KC, Schoenfeld AJ, Vokes NI, Luo J. Di Federico A, et al. Among authors: sholl lm. Ann Oncol. 2024 Dec 3:S0923-7534(24)04951-2. doi: 10.1016/j.annonc.2024.11.014. Online ahead of print. Ann Oncol. 2024. PMID: 39637943
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.
Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi JV, Lamberti G, Gandhi M, Di Federico A, Pecci F, Wang X, Makarem M, Hidalgo Filho CM, Gorria T, Saini A, Pabon C, Lindsay J, Pfaff KL, Welsh EL, Nishino M, Sholl LM, Rodig S, Kilickap S, Rietschel P, McIntyre DA, Pouliot JF, Altan M, Gainor JF, Heymach JV, Schoenfeld AJ, Awad MM. Ricciuti B, et al. Among authors: sholl lm. JTO Clin Res Rep. 2024 Apr 12;5(9):100675. doi: 10.1016/j.jtocrr.2024.100675. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39399157 Free PMC article.
The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer.
Roy-Chowdhuri S, Mani H, Fox AH, Tsao A, Sholl LM, Farjah F, Johnson BE, Osarogiagbon RU, Rivera MP, Silvestri GA, Smith RA, Wistuba II. Roy-Chowdhuri S, et al. Among authors: sholl lm. Cancer. 2024 Dec 15;130(24):4200-4212. doi: 10.1002/cncr.34926. Epub 2024 Sep 30. Cancer. 2024. PMID: 39347608 Free PMC article.
Fluorescence in-situ hybridization assessment of spindle cell-rich testicular sex cord stromal tumors demonstrates multiple chromosomal gains across histologic subtypes.
Acosta AM, Fletcher CDM, Sholl LM, van Leenders GJ, Oliva E, Cornejo KM, Repetto F, Collins K, Idrees MT, Hirsch MS, Trpkov K, Ulbright TM, Bridge JA. Acosta AM, et al. Among authors: sholl lm. Hum Pathol. 2024 Nov;153:105652. doi: 10.1016/j.humpath.2024.105652. Epub 2024 Aug 30. Hum Pathol. 2024. PMID: 39218045
317 results